Dow Down0.06% Nasdaq Up0.09%

NanoViricides, Inc. (NNVC)

1.31 Down 0.09(6.14%) 11:20AM EST - Nasdaq Real Time Price
ProfileGet Profile for:
NanoViricides, Inc.
1 Controls Drive
Shelton, CT 06484
United States - Map
Phone: 203-937-6137
Fax: 203-859-5095

Index Membership:N/A
Industry:Drug Manufacturers - Major
Full Time Employees:6

Business Summary 

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; Nanoviricide anti-viral eye drops against external eye viral infections; DengueCide, a treatment against Dengue viruses; RabiCide, an anti-rabies nanoviricide; and Nanoviricide for the treatment of various strains of Ebola and Marburg filoviruses. The company has licenses to develop drugs for the treatment of human viral diseases, such as H5N1 (avian flu), human influenza, HIV/AIDS, hepatitis B virus, hepatitis C virus, herpes simplex virus, and rabies; and dengue viruses, Japanese encephalitis virus, West Nile virus, viruses causing viral conjunctivitis and ocular herpes, and Ebola/Marburg viruses, as well as viral diseases of the eye comprising epidemic kerato-conjunctivitis and herpes keratitis. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on NanoViricides, Inc.

Corporate Governance 
NanoViricides, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 6. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 6; Compensation: 4.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Anil R. Diwan Ph.D., 57
Chairman, Pres and Sec.
Dr. Eugene Seymour M.D., MPH, 75
Chief Exec. Officer and Director
Ms. Meeta R. Vyas SB, MBA, 57
Chief Financial Officer
Dr. Randall W. Barton Ph.D., 69
Chief Scientific Officer and Chief Regulatory Officer
Dr. Jayant Tatake Ph.D.,
VP of R&D
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders